• News
  • SAN DIEGO
  • BioTech

Stephen Biggar elected to Acadia Pharmaceuticals board

San Diego biopharmaceutical company Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), announced Tuesday the election of Dr. Stephen R. Biggar to its board of directors.

He will fill a vacancy on Acadia’s board and serve as a Class II director, the company said in a release, and his term will expire at the annual meeting of stockholders in 2015.

Referring to what were reported as successful results in Acadia's recent Parkinson’s disease psychosis trial using the company's drug pimavanserin, Biggar said in the release that he shares in Acadia’s enthusiasm and belief that the drug has the potential to transform the treatment landscape for Parkinson's patients.

"Following the recent financing, which raised $86 million, Acadia has a solid foundation for building the full potential of pimavanserin," Biggar said. "I look forward to being a part of the Acadia team as we work to develop and commercialize pimavanserin and other potential new drugs that may improve the lives of patients.”

Biggar is a partner at Baker Brothers Investments, a fund management company focused on long-term investments in life sciences companies. From April 2002 to October 2006, he served as a principal with the fund.

He also serves as a director for Synageva BioPharma Corp. (Nasdaq: GEVA), a publicly traded biotechnology company.

Biggar received a master's degree and a Ph.D. in immunology from Stanford University, and received a bachelor's degree in genetics from the University of Rochester.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Subscribe Today!